Immunis, Inc.
Clinical trials sponsored by Immunis, Inc., explained in plain language.
-
New hope for sarcopenic obesity: expanded access program opens
Disease control TEMPORARILY_NOT_AVAILABLEThis program offers expanded access to IMM01-STEM, an experimental treatment for sarcopenic obesity—a condition combining muscle loss and obesity. It is for patients who cannot join ongoing clinical trials due to location, eligibility, or other reasons. Participants receive weekl…
Sponsor: Immunis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Could stem cell secretions help seniors regain muscle strength?
Disease control OngoingThis phase 2 trial tests whether a substance called IMM01-STEM, made from secretions of stem cells, can safely improve muscle performance in seniors aged 60-80 who have both obesity and muscle weakness (sarcopenic obesity). Participants receive injections twice a week for a perio…
Phase: PHASE2 • Sponsor: Immunis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC